


## Arbutamine

<b>Cat. No.:</b>	HY-16056
<b>CAS No.:</b>	128470-16-6
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>23</sub> NO <sub>4</sub>
<b>Molecular Weight:</b>	317.38
<b>Target:</b>	Adrenergic Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Arbutamine is a short-acting, potent and nonselective $\beta$ -adrenoceptor agonist that increases heart rate, cardiac contractility, and systolic blood pressure <sup>[1]</sup> . Arbutamine is a catecholamine for a pharmacological cardiac stress agent <sup>[2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	$\beta$ -adrenoceptor <sup>[1]</sup>
<b>In Vivo</b>	Arbutamine (i.v.; 5, 10, 50, 100, and 250 ng/kg/min) increases mean heart rate, peak positive left ventricular pressure and its first time-derivative, and normal-zone myocardial thickening in 8 open-chest dogs (mean weight, 26.91 kg). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Ruiz M, et al. Arbutamine stress perfusion imaging in dogs with critical coronary artery stenoses: (99m)Tc-sestamibi versus (201)Tl. J Nucl Med. 2002 May;43(5):664-70.
- [2]. Nagarajan R, et al. A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent. Cardiovasc Drugs Ther. 1996 Mar;10(1):31-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**